PRODUCT TYPES – Page 20

Biologic endotoxin OOS during deviation investigation board review: data integrity checks for bioassays and analytical similarity packages

The first step in managing an OOS result is to identify the symptoms or signals present in the manufacturing environment. For biologic endotoxin testing, the following indicators might suggest potential…

Cleaning validation failure during CPV review: facility and HVAC risk mitigation

Recognizing the symptoms of a cleaning validation failure is critical for prompt intervention. Common signals may include:Click to read the full article.

Biologic stability failure (real-time/accelerated) during commercial manufacturing campaign: investigation strategy aligned to FDA/EMA expectations and comparability principles

Recognizing the symptoms of a biologic stability failure is paramount to initiating a timely investigation. Common signals include:Click to read the full article.

Blend uniformity OOS after cleaning cycle change: CAPA aligned to regulatory expectations

When a blend uniformity OOS scenario arises, the initial symptoms may vary, including:Click to read the full article.

Biologic cell culture contamination event during deviation investigation board review: how to justify rework/reprocessing vs rejection for biologic lots

Identifying the initial signals of cell culture contamination is imperative. Symptoms may come from various sources, including in-process observations, laboratory data alerts, or complaints from production staff. Common indicators include:Click…

Stability degradation after cleaning cycle change: GMP investigation and containment strategy

Initially, detecting stability degradation signals typically manifests through various symptoms:Click to read the full article.

Biologic container closure integrity failure during downstream purification scale-up: how to justify rework/reprocessing vs rejection for biologic lots

Recognizing the symptoms of container closure integrity failures is the first step in addressing the problem. Common indicators may vary based on operations but generally include:Click to read the full…

Potency variability after cleaning cycle change: GMP investigation and containment strategy

Identifying symptoms of potency variability typically begins with an analysis of laboratory and production data. Common signals include:Click to read the full article.

Biologic bioburden excursion pre-sterile filtration after single-use system supplier change: investigation strategy aligned to FDA/EMA expectations and comparability principles

Identifying the symptoms of a bioburden excursion early is critical for containment and investigation. Signs may include:Click to read the full article.

Cleaning validation failure after cleaning cycle change: GMP investigation and containment strategy

Identifying symptoms indicative of cleaning validation failure is essential in initiating an appropriate investigation. Common signals include:Click to read the full article.

Biologic sterility assurance gap after equipment qualification update: how to document root cause when multiple unit operations are involved

Identifying the initial signals of a sterility assurance gap is crucial. Symptoms may arise from multiple sources including microbiological testing failures, deviations noted in batch records, or unexpected complaints during…

Stability degradation during multi-product campaign: CAPA aligned to regulatory expectations

Identifying the signs of stability degradation is the first step in a successful investigation. Symptoms may manifest in various ways, often prompting a detailed review of processes. Common signals include:Click…